|
|
|
Amgen Acquiring Ilypsa for $420M
|
|
|
| June 4, 2007--Amgen is acquiring Ilypsa, a private company
developing non-absorbed drugs for renal disorders, for
$420 million. Ilypsa's lead drug candidate, ILY101, is a
phosphate binder for the treatment of hyperphosphatemia in
chronic kidney disease patients on hemodialysis. Amgen
|
|
|
|
|
|
|
